Claims
- 1. A monoclonal antibody that specifically recognizes a class or stimulant or hallucinogenic drug of abuse comprising d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, and (+/−) 3,4-methylenedioxyamphetamine, wherein said monoclonal antibody is generated by a hapten comprising (S)- or (R)-3-(5′-Carboxypentyloxy) methamphetamine hydrochloride.
- 2. The monoclonal antibody of claim 1, wherein said antibody is of murine origin.
- 3. The monoclonal antibody of claim 1, wherein said antibody is of human origin or contains portions of a human antibody.
- 4. An antibody fragment that specifically recognizes a class of stimulant or hallucinogenic drug of abuse comprising d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, and (+/−) 3,4-methylenedioxyamphetamine, wherein said antibody fragment is part of a monoclonal antibody generated by a hapten comprising (S)- or (R)-3-(5′-Carboxypentyloxy) methamphetamine hydrochloride.
- 5. The antibody fragment of claim 4, wherein said antibody fragment is of murine origin.
- 6. The antibody fragment of claim 4, wherein said antibody fragment is of human origin or contains portions of a human antibody.
- 7. A method of treating stimulant or hallucinogenic drug abuse and/or overdose, comprising the step of administering a pharmacological effective dose of the monoclonal antibody of claim 1 to an individual in need of such treatment.
- 8. The method of claim 7, wherein said stimulant or hallucinogenic drug is selected from the group consisting of d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, and (+/−) 3,4-methylenedioxyamphetamine.
- 9. A method of treating stimulant or hallucinogenic drug abuse and/or overdose, comprising the step of administering a pharmacological effective dose of the antibody fragment of claim 4 to an individual in need of such treatment.
- 10. The method of claim 9, wherein said stimulant or hallucinogenic drug is selected from the group consisting of d-methamphetamine, d-amphetamine, (+/−) 3,4-methylenedioxymethamphetamine, and (+/−) 3,4-methylenedioxyamphetamine.
CROSS-REFERENCE TO RELATED APPLICATION
This non-provisional patent application claims benefit of provisional patent application U.S. Ser. No. 60/198,902, filed Apr. 20, 2000, now abandoned.
FEDERAL FUNDING
This invention was produced in part using funds obtained through grant number R01 DA11560 from the National Institute on Drug Abuse. Consequently, the federal government has certain rights in this invention.
US Referenced Citations (8)
Foreign Referenced Citations (4)
Number |
Date |
Country |
343346 |
Nov 1989 |
EP |
574782 |
Dec 1993 |
EP |
WO-9203163 |
Mar 1992 |
WO |
WO-9749732 |
Dec 1997 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/198902 |
Apr 2000 |
US |